Corticosteroids in the treatment of diabetic macular edema
Authors:
Jana Štefaničková; Silvia Krajčovičová
Authors‘ workplace:
Klinika oftalmológie LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in:
Forum Diab 2021; 10(2): 121-128
Category:
Overview
Diabetic macular edema is the main cause of decreased vision in diabetic patients in developing countries. Pathogenesis is multifactorial, upregulation of vascular endothelial growing factor, oxidative stress, inflammation and different metabolic pathways lead to breakdown of hematoretinal barrier, loss of pericytes, endothelial cells tight junction disruption and formation of macular edema. For more than 30 years, lasercoagulation has been the gold standard in the treatment of diabetic macular edema. Although antivascular endothelial growing factors are the first – line treatment option in eyes with DME, corticosteroids have the important role as well. The main advantage of corticosteroids is their antiinflammatory, antiapoptotic, antiedematous and antiangiogenic effects. This treatment could be especially effective in pseudophakic patients poorly responsive or refractive to antiVEGF treatment, as well as method of choice in pregnant and lactating women or in patients unwilling to come for numerous monthly injections. Currently available triamcinolone acetonide has been used for many years, but is not approved for this indication yet. Intravitreal-steroid-related side effects are cataract and elevation of intraocular pressure corticosteroids are triamcinolon acetonide, dexamethasone and fluocinolone acetonide intravitreal implants, injection – related side effects are endophthalmitis, retinal detachment and bleeding. Sustained release of intravitreal implants of dexamethasone and fluocinolon reduce complications and decreased number of injections in the management of patients with diabetic macular edema.
Keywords:
corticosteroids, diabetic macular edema – dexamethasone – fluocinolone – retinal lasercoagulation – triamcinolone – vascular endothelial growing factor
Sources
1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103(12): 1796–1806.
2. Demirel S, Argo C, Agarwal A et al. Updated on clinical trials in diabetic macular edema. Middle East Afr J Ophthalmol 2016; 23(1): 3–12. Dostupné z DOI: <http://dx.doi.org/10.4103/0974–9233.172293>.
3. [UKPDS Study Group]. Intensive blood – glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. (UKPDS). Lancet 1998; 352(9131): 837– 853.
4. Nathan DM, Genuth S, Lachin J et al. ]The Diabetes Control and Complications Trial Research Group]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–986. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199309303291401>.
5. Funatsu H, Yamashita H, Ikeda T et al. Vitreous levels of interleukin- 6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110(9): 1690–1696. Dostupné z DOI: <http://dx.doi.org/10.1016/S0161–6420(03)00568–2>.
6. Funatsu H, Yamashita H, Sakata K et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112(5):806–816. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2004.11.045>.
7. Funatsu H, Noma H, Mimura T et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116(1): 73–79. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2008.09.037>.
8. Elman MJ, Bressler NM, Qin H et al. Diabetic Retinopathy Clinical Research Network. Expanded 2- year follow – up of ranibizumab plus prompt or deffered laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118(4): 609–614. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2010.12.033>.
9. Ridker Pm, Hennekens CH, Bouring JE et al. C- reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12): 836–843. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200003233421202>.
10. Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentrations of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia1999; 42(3): 351 -357. Dostupné z DOI: <http://dx.doi.org/10.1007/s001250051162>.
11. Funatus H, Yamashita H, Noma H et al. Aqueous humor levels of cytokines are associated to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243(1): 3–8. Dostupné z DOI: <http://dx.doi.org/10.1007/s00417–004–0950–7>.
12. Mirossay L, Mojžiš J et al. Základná farmakológia a farmakoterapia. Equilibria: Košice 2009: 185–186. ISBN 9788089284436.
13. Whitcup SM, Cidlowski JI, Csaky KG et al. Pharmacology of corticosteroids for diabetic macular edema. Invest Ophthalmol Vis Sci 2018; 59(1): 1–12. Dostupné z DOI: <http://dx.doi.org/10.1167/iovs.17–22259>.
14. Audren F, Tod M, Massin P et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435–3441. Dostupné z DOI: <http://dx.doi.org/10.1167/iovs.03–1110>.
15. Kim JE, Pollack JS, Miller DG et al. ISIS-DME: A Prospective, Randomized, Dose-Escalation Intravitreal Steroid Injection Study for Refractory Diabetic Macular Edema. Retina 2008; 28(5):735–740. Dostupné z DOI: <http://dx.doi.org/10.1097/IAE.0b013e318163194c>.
16. Beck RW, Edwards AR, Aiello LP et al. [Diabetic Retinopathy Clinical Research Network]. Three-year Follow Up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular Edema. Arch Ophthalmol 2009; 127(3): 245–251. Dostupné z DOI: <http://dx.doi.org/10.1001/archophthalmol.2008.610>.
17. Schwartz SG, Scott IU, Stewart MW et al. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol 2016; 10: 1723–1730. Dostupné z DOI: <http://dx.doi.org/10.2147/OPTH.S115546>.
18. Elman MJ, Ayala A, Bressler NM et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs. Deferred Laser Treatment: 5-year Randomized Trial Results. Ophthalmology 2015; 122(2): 375– 381. <http://dx.doi.org/10.1016/j.ophtha.2014.08.047>.
19. Googe J, Brucker AJ, Bressler NM et al. [Diabetic Retinopathy Clinical Research Network]. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema Following Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina 2011; 31(6): 1009–1027. Dostupné z DOI: <http://dx.doi.org/10.1097/IAE.0b013e318217d739>.
20. Chew E, Strauber S, Beck R et al. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone aceto nide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007; 114(6): 1190–1196. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2007.02.010>.
21. Karst SG, Lammer J, Mitsch C et al. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 2018; 256(1): 49–58. Dostupné z DOI: <http://dx.doi.org/10.1007/s00417–017–3828–1>.
22. Urias EA, Urias GA, Monickaraj F et al. Novel therapeutic targets in diabetic macular edema: Beyond VEGF. Vision Res 2017; 139: 221– 227. Dostupné z DOI: <http://dx.doi.org/10.1016/j.visres.2017.06.015>.
23. Campochiaro PA, Wykoff CC, Brown DM et al. Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. Ophthalmol Retina 2018; 2(4): 320–328. Dostupné z DOI: <http://dx.doi.org/10.1016/j.oret.2017.07.013>.
24. Wykoff CC. Visual acuity gains seen in HULK trial. Healio Ophtalmology [online]. [13–11–2017]. Dostupné z WWW: <https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bfcd4aff1–8064–4698-a608-dbc0a890d92e%7D/visual-acuity-gains-seen-in-hulk-trial>.
25. Chang Lin JE, Burke JA, Peng Q et al. Pharmacokinetics of a sustained – release dexamethasone intravitreal implant in vitrectomized and non vitrectomized eyes. Invest Ophthlamol Vis Sci 2011; 52(7): 4605–4609. Dostupné z DOI: <http://dx.doi.org/10.1167/iovs.10–6387>.
26. Boyer DS, Yoon YH, Beflort R Jr et al. Ozurdex MEAD Study Group. Three – year randomized, sham – controlled of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthamology 2014; 121(10): 1904–1914. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2014.04.024>.
27. Callanan DG, Gupta S, Boyer DS et al. [Ozurdex PLACID Study Group]. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120(9): 1843–1851. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2013.02.018>.
28. Gillies MC, Lim LL, Campain A et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121(12): 2473–2481. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2014.07.002>.
29. Boyer DS, Faber D, Gupta S et al. [Ozurdex Champlain Study Group]. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31(5): 915–923. Dostupné z DOI: <http://dx.doi.org/10.1097/IAE.0b013e318206d18c>.
30. Maturi RK, Glassman AR, Liu D et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular EdemaA DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 2018; 136(1): 29–38. Dostupné z DOI: <http://dx.doi.org/10.1001/jamaophthalmol.2017.4914>.
31. Busch C, Zur D, Frasel-Bell S et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 2018; 55(8): 789–796. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592–018–1151-x>.
32. Campochiaro PA, Brown DM, Pearson A et al.] FAME study gruop]. Long –term benefit of sustained--delivery fluocinolone acetonid vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118(4): 626–635. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2010.12.028>.
33. Campochiaro PA, Brown DM, Pearson A et al. [FAME study group]. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119(10): 2125–2132. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2012.04.030>.
34. Figueira J, Henriques J, Amaro M et al. A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND). Ophthalmic Res 2017; 57(3): 166–172. Dostupné z DOI: <http://dx.doi.org/10.1159/000455235>.
35. Massin P, Erginay A, Dupas B et al. Efficacy and safety of sustained- delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clinical Ophthalmol 2016; 10: 1257– 1264. Dostupné z DOI: <http://dx.doi.org/10.2147/OPTH.S105385>.
36. Pessoa B, Coelho J, Correia N et al. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Ophthalmic Res 2018; 59(2): 68–75. Dostupné z DOI: <http://dx.doi.org/10.1159/000484091>.
37. Agarwal A, Parriott J, Demirel S et al. Nonbiological pharmacotherapies for the treatment of diabetic macular edema. Expert Opin Pharmacother 2015; 16(17): 2625–2635. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2015.1100172>.
38. Yang Y, Bailey C, Loewenstein A et al. Intravitreal corticosteroids in diabetic macular edema. Pharmacokinetic Considerations. Retina 2015; 35(12): 2440–2449. Dostupné z DOI: <http://dx.doi.org/10.1097/IAE.0000000000000726.>.
39. Zur D, Iglicki M, Loewenstien A. Steroids in the managment of diabetic macular edema. Ophtghalmic Res 2019; 62(4): 231–236. Dostupné z DOI: <http://dx.doi.org/10.1159/000499540>.
40. Concillado M, Lund-Anderson H, Mathiesen ER et al. Dexamethasone intravitreal implant for diabetic macular edema during pregnancy. Am J Ophthalmol 2016; 165: 7–15. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajo.2016.02.004>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
![Issue 2](https://www.forumdiabetologicum.sk/media/cache/resolve/journal_issue/media/image/e9260419a27294cae7522421dbd6019e.jpg)
Most read in this issue
- Catheter ablation of atrial fibrillation in patients with diabetes mellitus
- Left ventricular hypertrophy in patients with diabetes mellitus: what we don‘t think about?
- Alternative ways of insulin application
- Cardioprotective effect of treatment by GLP-1 analogues in the view of results of newest clinical studies